Phoenix, AZ -- March 09, 2021
-- InvestorsHub NewsWire -- The Stock Day Podcast welcomed
BioLargo, Inc. (OTCQB:BLGO),
a company that invents,
develops, and commercializes innovative platform technologies to
solve challenging environmental problems like PFAS contamination,
advanced water and wastewater treatment, air quality control, and
infection control. President and CEO of BioLargo, Dennis P.
Calvert, joined Stock Day host Everett Jolly.
Jolly began the interview by
asking about BioLargo's current projects. "This is a company that's
done the work to prove out technical innovations," said Calvert.
"We focus on clean air, clean water, and a clean Earth, so we're an
environmental engineering group, and we have incredible innovations
that are finding their way to market," he continued. "We're really
a sustainable solutions provider."
"Please give my listeners an
update on your PFAS solution. Does it really work, how big is it,
and what is the opportunity going forward?", asked Jolly. "The
Biden Administration has really made this a priority," explained
Calvert, adding that PFAS can be found in our water, bodies, and
products. "It has been linked to adverse health
effects."
"We started on PFAS about a
year and a half to two years ago, and we are now building our first
commercial units. We have four commercial trials, two are confirmed
and two are in the works," shared Calvert. "This is big
business."
Jolly then asked about the
company's balance sheet improvements over the past two to three
quarters, specifically related to the reduction of debt
obligations. "We have this depth of talent that would rival the
largest companies in the world," said Calvert. "We took some risks,
we brought in a lot of money, we had some debt, it was expensive,"
he continued. "Now that's coming to an end," said Calvert. "A very
small number will come due in August, it's convertible," he
explained. "All in, it was about $5 million, and we're down to
about $400,000 [in corporate debt obligations]," Calvert added.
"The future is so bright, the commercial opportunities are so
expansive, and the innovations are the real deal."
The conversation then turned to
the Company's Garratt-Callahan partnership. "First of all, this is
just a wonderful company. They're a hundred plus years old, they
are a national player, and they have a huge sales force," said
Calvert. Added Calvert, "Since the inception, we thought [the
relationship] would expand beyond the initial focus and it has.
We're already working on some projects with some of their clients,
and that is the start of something that could be really
great."
"Why should investors take a
look at BioLargo?", asked Jolly. Calvert responded, "The things we
are doing are massive, and the technology is proven. Now we get to
enjoy the adoption cycle. This is a company that is highly
committed to investing in the business, deferring [management]
compensation, and making sure that this company has the right
people and the tools to go out and do something extraordinarily
special. Everything we are doing we believe is number one in its
category."
To hear Dennis Calvert's entire
interview, follow the link to the podcast here: https://audioboom.com/posts/7818110-biolargo-inc-discusses-commercial-pfas-treatment-trials-and-garratt-callahan-partnership-with-t
Investors Hangout is a proud
sponsor of "Stock Day," and Stock Day Media encourages listeners to
visit the company's message board at https://investorshangout.com/
About
BioLargo, Inc.
BioLargo, Inc.
(OTCQB:BLGO) invents, develops, and commercializes innovative
platform technologies to solve challenging environmental problems
like PFAS contamination, advanced water and wastewater treatment,
industrial odor and VOC control, air quality control, and infection
control. With over 13 years of extensive R&D, BioLargo holds a
wide array of issued patents, maintains a robust pipeline of
products, and provides full-service environmental engineering. Our
peer-reviewed scientific approach allows us to invent or acquire
novel technologies and develop them to maturity through our
operating subsidiaries. With a keen emphasis on collaborations with
academic, municipal, and commercial organizations and associations,
BioLargo has proven itself with over 80 awarded grants and numerous
pilot projects. We monetize through direct sales, recurring service
contracts, licensing agreements, strategic joint venture formation
and/or the sale of the IP. Several of our technologies are
commercially available and are advancing as disrupters in their
respective markets. See our website at www.BioLargo.com.
Contact
Information
Dennis P.
Calvert
President and
CEO, BioLargo, Inc.
888-400-2863
Safe Harbor
Act - Caution Regarding Forward-Looking Statements
This press
release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. These
forward-looking statements include without limitation those about
BioLargo's (the "Company") expectations regarding the impact of the
COVID-19 pandemic; anticipated revenue; and plans for future
operations. These statements involve risks and uncertainties, and
actual results may differ materially from any future results
expressed or implied by the forward-looking statements. Risks and
uncertainties include without limitation: the effect of the
COVID-19 pandemic on the Company's business, results of operations,
financial condition, and stock price; the effect of regional
economic conditions on the Company's business, including effects on
purchasing decisions by consumers and businesses; the ability of
the Company to compete in markets that are highly competitive and
subject to rapid technological change; the ability of the Company
to manage frequent introductions and transitions of products and
services, including delivering to the marketplace, and stimulating
customer demand for, new products, services, and technological
innovations on a timely basis; the dependency of the Company on the
performance of distributors of the Company's products. More
information on these risks and other potential factors that could
affect the Company's business and financial results is included in
the Company's filings with the SEC, including in the "Risk Factors"
and "Management's Discussion and Analysis of Financial Condition
and Results of Operations" sections of the Company's most recently
filed periodic reports on Form 10-K and Form 10-Q and subsequent
filings. The Company assumes no obligation to update any
forward-looking statements or information, which speak as of their
respective dates.
About The
"Stock Day" Podcast
Founded in 2013, Stock Day is
the fastest growing media outlet for Nano-Cap and Micro-Cap
companies. It educates investors while simultaneously working with
penny stock and OTC companies, providing transparency and
clarification of under-valued, under-sold Micro-Cap stocks of the
market. Stock Day provides companies with customized solutions to
their news distribution in both national and international media
outlets. The Stock Day Podcast is the number one radio show of its
kind in America.
SOURCE:
Stock Day Media
(602)
821-1102
BioLargo (QX) (USOTC:BLGO)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025
BioLargo (QX) (USOTC:BLGO)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025
